Literature DB >> 18760301

Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.

David C Fritzinger1, Brian E Hew, Mike Thorne, Michael K Pangburn, Bert J C Janssen, Piet Gros, Carl-Wilhelm Vogel.   

Abstract

Cobra venom factor (CVF) is a structural and functional analog of complement C3 isolated from cobra venom. Both CVF and C3b can bind factor B and subsequently form the bimolecular C3/C5 convertases CVF,Bb or C3b,Bb, respectively. The two homologous enzymes exhibit several differences of which the difference in physico-chemical stability is most important, allowing continuous activation of C3 and C5 by CVF,Bb, leading to serum complement depletion. Here we describe the detailed functional properties of two hybrid proteins in which the 113 or 315 C-terminal residues of C3 were replaced with corresponding CVF sequences. Both hybrid proteins formed stable convertases that exhibited C3-cleaving activity, although at different rates. Neither convertase cleaved C5. Both convertases showed partial resistance to inactivation by factors H and I, allowing them to deplete complement in human serum. These data demonstrate that functionally important structural differences between CVF and C3 are located in the very C-terminal region of both homologous proteins, and that small substitutions in human C3 with homologous CVF sequence result in C3 derivatives with CVF-like functions. Such hybrid proteins are important tools to study the structure/function relationships in both C3 and CVF, and these "humanized CVF" proteins may become reagents for therapeutic complement depletion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18760301     DOI: 10.1016/j.dci.2008.07.006

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  8 in total

1.  Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.

Authors:  Bert J C Janssen; Lucio Gomes; Roman I Koning; Dmitri I Svergun; Abraham J Koster; David C Fritzinger; Carl-Wilhelm Vogel; Piet Gros
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

Review 2.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

3.  Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

Authors:  Siao-Yi Wang; Suresh Veeramani; Emilian Racila; Jeffrey Cagley; David C Fritzinger; Carl-Wilhelm Vogel; William St John; George J Weiner
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

4.  Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury.

Authors:  W Brian Gorsuch; Benjamin J Guikema; David C Fritzinger; Carl-Wilhelm Vogel; Gregory L Stahl
Journal:  Mol Immunol       Date:  2009-09-10       Impact factor: 4.407

5.  Complement C3 is a novel modulator of the anti-factor VIII immune response.

Authors:  Julie Rayes; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Laurent Gilardin; Carl-Wilhelm Vogel; David C Fritzinger; Véronique Frémeaux-Bacchi; Srinivas V Kaveri; Lubka T Roumenina; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

Review 6.  Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.

Authors:  József Dobó; Andrea Kocsis; Péter Gál
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 7.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

8.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.